• Yoshiko Kaneko, Takako Mouri, Yurie Seto, Naoya Nishioka, Akihiro Yoshimura, Chie Yamamoto, Sachi Harita, Yusuke Chihara, Nobuyo Tamiya, Tadaaki Yamada, Junji Uchino, and Koichi Takayama.
• Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Japan.
• Intern. Med. 2020 Jan 1; 59 (13): 1605-1610.

AbstractObjective Patients with suspected lung cancer often experience adverse side effects such as anxiety, depression, and a decreased appetite. These side effects influence the patients' quality of life and their ability to make decisions concerning appropriate treatment. This study examined the psychological status and quality of life of patients with suspected lung cancer before and after bronchoscopy treatment and evaluated the effect of mirtazapine prescribed to patients with depression. Methods To assess patient characteristics (e.g. age, gender, and medical history), a questionnaire including the Hospital Anxiety and Depression Scale - Japanese version and the Functional Assessment of Cancer Therapy-L was administered. Patients Forty-three patients admitted for bronchoscopy treatment between May 2017 and April 2018 were included. Results The results showed that patients with depression reported a worse quality of life than those without depression. Compared with no medication, the administration of mirtazapine alleviated depressive symptoms. Furthermore, the patients' depressive status was affected by their physical symptoms, including coughing, tightness of chest, and dyspnea. Conclusion Our results emphasize the importance of detecting depression in the early stages of a cancer diagnosis and have significant implications concerning pharmacological intervention in patients with cancer displaying signs of depression.

20 keywords...

hide…